Pennsylvania Trust Co grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 79.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,600 shares of the pharmaceutical company’s stock after purchasing an additional 1,155 shares during the period. Pennsylvania Trust Co’s holdings in Vertex Pharmaceuticals were worth $390,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in VRTX. Vanguard Group Inc. grew its holdings in Vertex Pharmaceuticals by 3.1% during the second quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock worth $2,188,196,000 after acquiring an additional 504,982 shares during the period. Jennison Associates LLC grew its holdings in Vertex Pharmaceuticals by 19.0% during the third quarter. Jennison Associates LLC now owns 6,017,766 shares of the pharmaceutical company’s stock worth $914,941,000 after acquiring an additional 962,644 shares during the period. Orbimed Advisors LLC grew its holdings in Vertex Pharmaceuticals by 2.4% during the third quarter. Orbimed Advisors LLC now owns 2,074,302 shares of the pharmaceutical company’s stock worth $315,377,000 after acquiring an additional 47,800 shares during the period. Bank of New York Mellon Corp grew its holdings in Vertex Pharmaceuticals by 0.6% during the third quarter. Bank of New York Mellon Corp now owns 1,994,410 shares of the pharmaceutical company’s stock worth $303,230,000 after acquiring an additional 12,454 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in Vertex Pharmaceuticals by 3.2% during the third quarter. Wells Fargo & Company MN now owns 1,977,269 shares of the pharmaceutical company’s stock worth $300,624,000 after acquiring an additional 61,042 shares during the period. 93.19% of the stock is currently owned by institutional investors and hedge funds.
Several analysts recently commented on VRTX shares. Vetr lowered Vertex Pharmaceuticals to a “sell” rating in a report on Thursday, September 21st. Zacks Investment Research raised Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $174.00 target price on the stock in a report on Tuesday, September 26th. BMO Capital Markets reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, September 27th. BTIG Research started coverage on Vertex Pharmaceuticals in a report on Friday, September 29th. They set a “buy” rating and a $200.00 target price on the stock. Finally, DA Davidson started coverage on Vertex Pharmaceuticals in a report on Friday, September 29th. They set a “buy” rating and a $200.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twenty-five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $175.89.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $157.19 on Friday. The stock has a market capitalization of $39,703.21, a P/E ratio of 201.53, a price-to-earnings-growth ratio of 1.85 and a beta of 1.58. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 1 year low of $80.06 and a 1 year high of $167.85.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.49. The company had revenue of $578.20 million for the quarter, compared to the consensus estimate of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. Vertex Pharmaceuticals’s revenue for the quarter was up 39.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.16 earnings per share. equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current fiscal year.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.